CLINDAMYCIN PHOSPHATE
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
| Metabolism | Hepatic metabolism primarily via CYP3A4 to active and inactive metabolites; some metabolism via non-CYP pathways. |
| Excretion | Renal 10% unchanged, fecal/biliary 90% as metabolites (mostly inactive) |
| Half-life | Terminal half-life 2-4 hours (prolonged to 8-12 hours in severe hepatic impairment; unchanged in renal failure) |
| Protein binding | 90-95% bound primarily to albumin |
| Volume of Distribution | 0.6-1.2 L/kg (wide distribution, penetrates most tissues except CNS; accumulates in bone and abscesses) |
| Bioavailability | Oral: 30-50% (dose-dependent); IM: 85-90% |
| Onset of Action | Oral: 0.5-1 hour; IM: 1-2 hours; IV: rapid (within minutes) |
| Duration of Action | Oral: 6-8 hours; IM: 8-12 hours; IV: 6-8 hours (bacteriostatic; duration can vary with dose and infection site) |
| Molecular Weight | 504.96 |
| Action Class | Lincosamides |
| Brand Substitutes | Acneclin Gel, Clinof Gel, Clincitop Gel, Aclind Gel, Camyda Gel |
600 mg IV every 8 hours or 300-450 mg PO every 6 hours
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR <30 mL/min, no adjustment needed but monitor for accumulation with high doses. |
| Liver impairment | Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or use with caution. |
| Pediatric use | 10-25 mg/kg/day IV in 3-4 divided doses or 8-20 mg/kg/day PO in 3-4 divided doses; maximum dose 1800 mg/day IV. |
| Geriatric use | No specific dose adjustment; use lower end of dosing range due to potential renal impairment and increased risk of adverse effects. |
| 1st trimester | Use only if clearly needed; no well-controlled studies in pregnant women, but animal studies have not shown fetal risk. |
| 2nd trimester | Use only if clearly needed; no evidence of harm in second trimester. |
| 3rd trimester | Use only if clearly needed; potential for neonatal diarrhea or colitis if given near term. |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Placental transfer | Crosses the placenta; fetal serum levels reach approximately 50% of maternal levels. |
| Breastfeeding |
■ FDA Black Box Warning
Clindamycin can cause severe, sometimes fatal, Clostridium difficile-associated diarrhea (CDAD).
| Serious Effects |
Hypersensitivity to clindamycin or lincomycinHistory of pseudomembranous colitis or antibiotic-associated colitis
| Precautions | Clostridium difficile-associated diarrhea (CDAD), hypersensitivity reactions, severe skin reactions (e.g., Stevens-Johnson syndrome), neuromuscular blocking effects, colitis, prolonged use leading to superinfection, hepatic impairment, renal impairment. |
| Food/Dietary | No significant food interactions; take with or without food. Alcohol may increase gastrointestinal side effects. |
Loading safety data…
| Clindamycin is excreted into breast milk in low amounts. While generally considered compatible with breastfeeding, use with caution due to potential for gastrointestinal effects (e.g., diarrhea, colitis) in the nursing infant. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Clindamycin phosphate is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. No known teratogenic effects in first trimester; potential for alteration of neonatal gut flora if used near term. |
| Fetal Monitoring | Monitor maternal liver function tests and renal function periodically. Observe for signs of pseudomembranous colitis. In prolonged therapy, monitor blood counts. Fetal monitoring is not typically required; assess fetal heart rate patterns if used during labor for group B streptococcus prophylaxis. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data indicate significant impact on fertility. |
| Clinical Pearls |
| Clindamycin phosphate is a prodrug that must be hydrolyzed to active clindamycin. Topical formulations can cause pseudomembranous colitis due to systemic absorption. Avoid coadministration with macrolides due to antagonism. Monitor liver function in hepatic impairment. |
| Patient Advice | Take clindamycin with a full glass of water to prevent esophageal irritation. · Complete the entire course even if symptoms improve. · Report severe diarrhea, abdominal cramps, or bloody stools immediately. · Avoid alcohol during treatment and for 3 days after stopping. |